Conde, E.; Earl, J.; Crespo-Toro, L.; Blanco-Agudo, C.; Ramos-Muñoz, E.; Rodríguez-Serrano, E.M.; Martínez Ávila, J.C.; Salinas-Muñoz, L.; Serrano-Huertas, S.; Ferreiro, R.;
et al. Biomarkers Associated with Regorafenib First-Line Treatment Benefits in Metastatic Colorectal Cancer Patients: REFRAME Molecular Study. Cancers 2021, 13, 1710.
https://doi.org/10.3390/cancers13071710
AMA Style
Conde E, Earl J, Crespo-Toro L, Blanco-Agudo C, Ramos-Muñoz E, Rodríguez-Serrano EM, Martínez Ávila JC, Salinas-Muñoz L, Serrano-Huertas S, Ferreiro R,
et al. Biomarkers Associated with Regorafenib First-Line Treatment Benefits in Metastatic Colorectal Cancer Patients: REFRAME Molecular Study. Cancers. 2021; 13(7):1710.
https://doi.org/10.3390/cancers13071710
Chicago/Turabian Style
Conde, Elisa, Julie Earl, Lorena Crespo-Toro, Carolina Blanco-Agudo, Edurne Ramos-Muñoz, E. Macarena Rodríguez-Serrano, Jose Carlos Martínez Ávila, Laura Salinas-Muñoz, Silvia Serrano-Huertas, Reyes Ferreiro,
and et al. 2021. "Biomarkers Associated with Regorafenib First-Line Treatment Benefits in Metastatic Colorectal Cancer Patients: REFRAME Molecular Study" Cancers 13, no. 7: 1710.
https://doi.org/10.3390/cancers13071710
APA Style
Conde, E., Earl, J., Crespo-Toro, L., Blanco-Agudo, C., Ramos-Muñoz, E., Rodríguez-Serrano, E. M., Martínez Ávila, J. C., Salinas-Muñoz, L., Serrano-Huertas, S., Ferreiro, R., Rodriguez-Garrote, M., Sainz, B., Jr., Massuti, B., Alfonso, P. G., Benavides, M., Aranda, E., García-Bermejo, M. L., & Carrato, A.
(2021). Biomarkers Associated with Regorafenib First-Line Treatment Benefits in Metastatic Colorectal Cancer Patients: REFRAME Molecular Study. Cancers, 13(7), 1710.
https://doi.org/10.3390/cancers13071710
